NEW YORK, Nov. 18, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers.  Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies. 

Kuehn Law is investigating whether the Boards of the below companies 1) acted to maximize shareholder value, 2) failed to disclose material information, and 3) conducted a fair process: 

NEW YORK, Nov. 15, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Barnes Group Inc. (NYSE: B)'s sale to funds managed by affiliates of Apollo Global Management, Inc. for $47.50 per share in cash. If you are a Barnes shareholder, click here to learn more about your legal rights and options.

NEW YORK, Nov. 12, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Barnes Group Inc. (NYSE: B)'s sale to funds managed by affiliates of Apollo Global Management, Inc. for $47.50 per share in cash. If you are a Barnes shareholder, click here to learn more about your legal rights and options.

NEW YORK, Nov. 6, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Smartsheet Inc. (NYSE: SMAR)'s sale to funds managed by Blackstone and Vista Equity Partners for $56.50 per share in cash. If you are a Smartsheet shareholder, click here to learn more about your legal rights and options.

STOCKHOLM, Nov. 6, 2024 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ: BIOA B) (STOCKHOLM: BIOA B) has presented the design of its proprietary BrainTransporter (BT) platform at the 16th annual Protein & Antibody Engineering Summit (PEGS) conference in Barcelona, Spain. The BT platform uses active Transferrin Receptor (TfR)-mediated transport, enabling up to 70-fold higher penetration of antibodies over the blood brain barrier, without negative effects on hematological safety parameters.

During the 16th annual Protein & Antibody Engineering Summit (PEGS) Europe conference, Dr. Per-Ola Freskgård, VP Science & Technology at BioArctic, presented for the first time the design of the proprietary BT platform as well as validation in preclinical models.

STOCKHOLM, Nov. 6, 2024 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ: BIOA B) (STOCKHOLM: BIOA B) has presented the design of its proprietary BrainTransporter (BT) platform at the 16th annual Protein & Antibody Engineering Summit (PEGS) conference in Barcelona, Spain. The BT platform uses active Transferrin Receptor (TfR)-mediated transport, enabling up to 70-fold higher penetration of antibodies over the blood brain barrier, without negative effects on hematological safety parameters.

During the 16th annual Protein & Antibody Engineering Summit (PEGS) Europe conference, Dr. Per-Ola Freskgård, VP Science & Technology at BioArctic, presented for the first time the design of the proprietary BT platform as well as validation in preclinical models.

NEW YORK, Nov. 1, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies. 

Kuehn Law is investigating whether the Boards of the below companies 1) acted to maximize shareholder value, 2) failed to disclose material information, and 3) conducted a fair process: 

LINKÖPING, Sweden, Oct. 30, 2024 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) has signed an enterprise imaging contract with Belgium's largest university hospital, UZ Leuven. The healthcare provider will utilize the module for digital pathology, providing pathologists with a digital solution designed for full-scale primary diagnostics. This will save valuable time for both clinicians and patients, further enhancing cancer care.

"We have been using digital pathology in a limited capacity for multiple years. As we now take the step to go fully digital for primary diagnostics, we want to ensure to have a solution that both provides pathologists with a state-of-the-art application and gives us the freedom to optimize our choice of related software and scanners," says Prof. Dr. Thomas Tousseyn, hematopathologist at UZ Leuven.

NEW YORK, Oct. 25, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Barnes Group Inc. (NYSE: B)'s sale to funds managed by affiliates of Apollo Global Management, Inc. for $47.50 per share in cash. If you are a Barnes shareholder, click here to learn more about your legal rights and options.

STOCKHOLM, Oct. 24, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) founder Lars Lannfelt will be presented with the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research at the Clinical Trials for Alzheimer's Disease Conference (CTAD) held in Madrid, Spain, and virtually from October 29 to November 1. Lars Lannfelt will be one of the keynote speakers at the conference. In addition, BioArctic's partner Eisai present lecanemab data in two oral and one poster presentation at the meeting and three symposia will focus on lecanemab. Data shared will include the importance of continued treatment of Alzheimer's disease, a progressive neurodegenerative disease that begins before plaque deposition and continues after plaque removal.